Document Classification

Section Type: RESULTS

Text: Compared with tesamorelin nonresponders, responders experienced greater mean (SD) reduction in triglyceride levels (26 weeks : -0. 6 1. 7 mmol/L vs -0. 1 1. 2 mmol/L [P =. 005] ; 52 weeks : -0. 8 1. 8 mmol/L vs 0. 0 1. 1 mmol/L [P =. 003]) and attenuated changes in fasting glucose levels (26 weeks : 1 16 mg/dL vs 5 14 mg/dL [P =. 01] ; 52 weeks : -1 14 mg/dL vs 8 17 mg/dL [P <. 001]), hemoglobin A1c levels (26 weeks : 0. 1 0. 3 % vs 0. 3 0. 4 % [P <. 001] ; 52 weeks : 0. 0 0. 3 % vs 0. 2 0. 5 % [P =. 003]), and other parameters of glucose homeostasis.